Study population characteristics in the training set and validation set
| Characteristic . | Training cohort, N = 282 . | P value for difference between GVHD− and GVHD+ . | Validation cohort, N = 142 . | P value for difference between GVHD− and GVHD+ . | P value for difference between training and validation sets . | ||
|---|---|---|---|---|---|---|---|
| GVHD−, N = 166 . | GVHD+, N = 116 . | GVHD−, N = 76 . | GVHD+, N = 66 . | ||||
| Age, y | |||||||
| Median | 43 | 49 | .02 | 47 | 52 | .17 | .15 |
| Range | 1–68 | 1–71 | 4–69 | 1–66 | |||
| Diagnostic, % (no.) | |||||||
| Malignant* | 93 (154) | 97 (113) | .15 | 97 (74) | 97 (64) | .71 | .35 |
| Other† | 7 (12) | 3 (3) | 3 (2) | 3 (2) | |||
| Disease status at BMT,‡% (no.) | |||||||
| Low risk | 58 (96) | 49 (57) | .19 | 64 (49) | 56 (37) | .39 | .14 |
| High risk | 42 (70) | 51 (59) | 36 (27) | 44 (29) | |||
| Donor type, % (no.) | |||||||
| MRD | 68 (113) | 58 (68) | .13 | 75 (57) | 58 (38) | .04 | .66 |
| URD | 32 (53) | 42 (48) | 25 (19) | 42 (28) | |||
| Donor match, % (no.) | |||||||
| Matched | 95 (157) | 87 (101) | .04 | 93 (71) | 83 (55) | .10 | .46 |
| Mismatched | 5 (9) | 13 (15) | 7 (5) | 17 (11) | |||
| Conditioning regimen intensity, % (no.) | |||||||
| Full | 73 (122) | 63 (73) | .08 | 79 (60) | 61 (41) | .04 | .76 |
| Reduced | 27 (44) | 37 (43) | 21 (16) | 37 (25) | |||
| Grade at GVHD onset, % (no.) | |||||||
| 0 | 59 (166) | 0 | 54 (76) | 0 | |||
| 1 | 0 | 12 (34) | 0 | 11 (15) | .31 | ||
| 2 | 0 | 23 (64) | 0 | 24 (35) | |||
| 3–4 | 0 | 6 (18) | 0 | 11 (16) | |||
| Organ target at GVHD onset, % (no.) | |||||||
| Skin | 0 | 66 (71) | 0 | 58 (38) | |||
| Gut | 0 | 18 (20) | 0 | 24 (16) | .64 | ||
| Liver | 0 | 4 (5) | 0 | 4 (3) | |||
| Combined | 0 | 12 (14) | 0 | 14 (9) | |||
| Day after BMT of samples | |||||||
| Median | 30 | 30 | .36 | 30 | 29 | .85 | .85 |
| Range | 7–104 | 5–119 | 7–99 | 7–112 | |||
| Characteristic . | Training cohort, N = 282 . | P value for difference between GVHD− and GVHD+ . | Validation cohort, N = 142 . | P value for difference between GVHD− and GVHD+ . | P value for difference between training and validation sets . | ||
|---|---|---|---|---|---|---|---|
| GVHD−, N = 166 . | GVHD+, N = 116 . | GVHD−, N = 76 . | GVHD+, N = 66 . | ||||
| Age, y | |||||||
| Median | 43 | 49 | .02 | 47 | 52 | .17 | .15 |
| Range | 1–68 | 1–71 | 4–69 | 1–66 | |||
| Diagnostic, % (no.) | |||||||
| Malignant* | 93 (154) | 97 (113) | .15 | 97 (74) | 97 (64) | .71 | .35 |
| Other† | 7 (12) | 3 (3) | 3 (2) | 3 (2) | |||
| Disease status at BMT,‡% (no.) | |||||||
| Low risk | 58 (96) | 49 (57) | .19 | 64 (49) | 56 (37) | .39 | .14 |
| High risk | 42 (70) | 51 (59) | 36 (27) | 44 (29) | |||
| Donor type, % (no.) | |||||||
| MRD | 68 (113) | 58 (68) | .13 | 75 (57) | 58 (38) | .04 | .66 |
| URD | 32 (53) | 42 (48) | 25 (19) | 42 (28) | |||
| Donor match, % (no.) | |||||||
| Matched | 95 (157) | 87 (101) | .04 | 93 (71) | 83 (55) | .10 | .46 |
| Mismatched | 5 (9) | 13 (15) | 7 (5) | 17 (11) | |||
| Conditioning regimen intensity, % (no.) | |||||||
| Full | 73 (122) | 63 (73) | .08 | 79 (60) | 61 (41) | .04 | .76 |
| Reduced | 27 (44) | 37 (43) | 21 (16) | 37 (25) | |||
| Grade at GVHD onset, % (no.) | |||||||
| 0 | 59 (166) | 0 | 54 (76) | 0 | |||
| 1 | 0 | 12 (34) | 0 | 11 (15) | .31 | ||
| 2 | 0 | 23 (64) | 0 | 24 (35) | |||
| 3–4 | 0 | 6 (18) | 0 | 11 (16) | |||
| Organ target at GVHD onset, % (no.) | |||||||
| Skin | 0 | 66 (71) | 0 | 58 (38) | |||
| Gut | 0 | 18 (20) | 0 | 24 (16) | .64 | ||
| Liver | 0 | 4 (5) | 0 | 4 (3) | |||
| Combined | 0 | 12 (14) | 0 | 14 (9) | |||
| Day after BMT of samples | |||||||
| Median | 30 | 30 | .36 | 30 | 29 | .85 | .85 |
| Range | 7–104 | 5–119 | 7–99 | 7–112 | |||
GVHD indicates graft-versus-host disease.
Malignant disease included acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin disease (HD), multiple myeloma (MM), juvenile myelomonocytic leukemia (JMML), and chronic lymphocytic leukemia (CLL).
Nonmalignant disease included severe congenital neutropenia (SCN), severe aplastic anemia, Wiskott-Aldrich syndrome, β-thalassemia, essential thrombocythemia, myelofibrosis, Glanzmann thrombasthenia, congenital amegakaryocytic thrombocytopenia, and sickle cell anemia.
Low and high risk of disease status at BMT according to IBMTR guidelines.